Skip to main content
. 2022 Feb 1;2022:5479491. doi: 10.1155/2022/5479491

Figure 3.

Figure 3

Radiotherapy combined with anti-PD-L1 and anlotinib could significantly potentiate the tumor immune microenvironment compared with other treatment combinations. Quantitative data and flow cytometric analysis of CD45+ T cells (a), CD4+T cells (b), CD8+ T cells (c), MDSCs (d), and M1 cells and M2 cells (e) in tumors. CTRL: control; RT: radiotherapy; IO: immunotherapy; AN: anlotinib.